Welcome to our dedicated page for Tharimmune news (Ticker: THAR), a resource for investors and traders seeking the latest updates and insights on Tharimmune stock.
Tharimmune, Inc., trading under the symbol THAR on NASDAQ, is a clinical-stage biotechnology company dedicated to developing therapeutic solutions for rare immune, inflammatory, and oncologic diseases. The company's primary focus is the advancement of its portfolio of therapeutic candidates, with a notable asset, TH104, aimed at treating chronic, debilitating pruritus in primary biliary cholangitis (PBC), a rare and orphan liver disease with no known cure.
Tharimmune is actively engaged in the development of novel multi-specific antibodies targeting unique epitopes in multiple solid tumors. These antibodies employ new mechanisms of action against validated targets, offering innovative solutions in the field of immuno-oncology. A key collaboration with OmniAb, Inc. allows Tharimmune to leverage advanced antibody discovery technology for these specified targets.
The company recently announced the pricing of an underwritten public offering, raising $10 million to fund its ongoing phase 2 trial for TH104, expected in 2024, and other general corporate purposes. This financial boost will support their clinical and non-clinical programs, ensuring sustained progress towards their mission.
In its latest Phase 1 trial conducted in India, TH104 demonstrated a significant reduction in pruritus among patients with chronic liver disease, with a 33.3% decrease in 24-hour mean itching intensity score. The trial also confirmed the safety of TH104, showing no unexpected treatment-emergent adverse events. These promising results lay the groundwork for an upcoming Phase 2a trial in the US, anticipated to yield pivotal data in 2024.
Tharimmune has consistently demonstrated a commitment to scientific excellence and patient care. Their ongoing research is poised to make significant contributions to the treatment of liver-related and other pruritogenic inflammatory conditions, as well as novel therapies for cancer treatment. With a strong pipeline and strategic partnerships, Tharimmune is well-positioned to lead advancements in biotechnology.
Tharimmune (NASDAQ:THAR), a clinical-stage biotechnology company, has appointed Prof. David Jones of Newcastle University to its Scientific Advisory Board (SAB). Prof. Jones, an expert in autoimmune liver disease, leads the UK-PBC research consortium and has contributed to stratified therapy in rare liver disease. He joins a newly formed SAB that includes experts from various prestigious institutions.
The company is advancing its lead drug candidate TH104 for pruritus secondary to primary biliary cholangitis (PBC). Tharimmune recently reported positive Phase 1 results for TH104 and received FDA feedback for its upcoming Phase 2 trial, expected to start in the second half of 2024.
Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company focused on inflammation and immunology, has appointed David H. Clarke as a Strategic Advisor to its executive management team. Clarke brings extensive experience in corporate governance, financial planning, and leadership across multiple industries, including biotechnology. His appointment is expected to provide strategic guidance as Tharimmune advances TH104 for treating pruritus in patients with primary biliary cholangitis and expands its pipeline.
Clarke's background includes serving as Chairman and CEO of United Pacific Industries and Jacuzzi Brands, as well as Vice Chairman and CEO of Hanson's U.S. division. His expertise in public company operations and leadership is anticipated to strengthen Tharimmune's organization and support its mission to deliver innovative treatments for unmet medical needs.
Tharimmune (NASDAQ:THAR), a clinical-stage biotech company, has launched a new website at www.tharimmune.com. The redesigned platform offers comprehensive information about the company's research, clinical trials, and corporate developments. CEO Randy Milby emphasized the website's role in enhancing communication with stakeholders.
Concurrently, Tharimmune is continuing discussions with the FDA regarding the design and initiation of a Phase 2 clinical trial for TH104, their lead candidate. The trial aims to address moderate-to-severe chronic pruritis in primary biliary cholangitis. The company expects to launch the Phase 2 trial in Q3 2024, following a productive Type C meeting with the FDA.
Tharimmune announced the appointment of Jules Haimovitz as a Strategic Advisor. Jules brings decades of experience in biotechnology, having served on several notable Boards of Directors. His expertise in corporate governance, strategic planning, and industry trends is expected to enhance Tharimmune's efforts in developing treatments for unmet medical needs.
CEO Randy Milby highlighted Jules' potential to strengthen Tharimmune's clinical and preclinical programs. This appointment is timely, aligning with recent positive FDA feedback on Tharimmune's Phase 2 program for TH104, a leading candidate for treating pruritus in patients with primary biliary cholangitis (PBC).
Jules, President of Haimovitz Consulting, Inc., also serves as a Director at Armata Pharmaceuticals and Innoviva. His experience will be important during Tharimmune's critical Phase 2 testing phase, expected to be a significant value inflection point for the company.
Tharimmune, a clinical-stage biotechnology company, announced a $2.08 million private placement for 659,545 shares of common stock and 329,771 warrants at $3.16 per share. The warrants are exercisable at $3.09 per share, starting six months post-issuance, expiring five and a half years later. The closing is set for June 21, 2024, led by President Street Global as the exclusive placement agent. The financing is spearheaded by SDS Capital Group with contributions from Gravitas Capital and other biotech investors. The funds will support Tharimmune's clinical development and working capital, primarily for their lead candidate, TH104, aimed at treating chronic pruritus in primary biliary cholangitis.
Tharimmune has received positive feedback from the FDA for its Phase 2 clinical trial of TH104, a transmucosal buccal film containing nalmefene, for treating moderate-to-severe pruritus in primary biliary cholangitis (PBC). This feedback supports Tharimmune's plan to pursue a 505(b)(2) approval pathway, allowing the use of existing data on the approved active ingredient. The FDA acknowledged that the nonclinical studies are adequate for Phase 2 trial initiation and provided recommendations on study design, patient inclusion, primary endpoints, and monitoring for adverse events. Tharimmune aims to start the trial in late 2024.
Tharimmune, a clinical-stage biotech firm, announced positive Phase 1 trial results for TH104, its lead candidate for moderate-to-severe pruritus in primary biliary cholangitis (PBC). The study in healthy subjects showed that the pharmacokinetic (PK) profile of oral transmucosal TH104 was comparable to intravenous nalmefene. Safety and tolerability were also on par, with mild side effects reported. The trial met its primary endpoint, demonstrating a 45.9% bioavailability for TH104. Planning for a Phase 2 trial in 2024 is on track, with discussions ongoing with the FDA.
The study involved 20 healthy subjects in a single-dose, open-label, randomized 2-way crossover format. Findings indicated that TH104 has a median time to maximum concentration (Cmax) of 2.0 hours and a half-life (T1/2) of 14 hours. Mild adverse effects like dizziness, nausea, and somnolence were noted. No serious adverse events occurred.
Tharimmune, a clinical-stage biotech firm specializing in inflammation and immunology therapies, will present at the 2024 BIO International Convention from June 3-6 in San Diego. The company will showcase its therapeutic candidates and hold one-on-one meetings with investors and industry leaders. The presentation is scheduled for June 3 at 1:45 p.m. PT in Company Presentation Theater 3. Interested parties can arrange meetings via the BIO One-on-One Partnering system or by contacting Tirth Patel of LHA Investor Relations.
Tharimmune, a clinical-stage biotechnology company, announced a 1-for-15 reverse stock split of its common stock, effective after the close of trading on May 24, 2024. The company's stock will trade on a post-split basis starting May 28, 2024, under the symbol 'THAR' and new CUSIP number 432705309. This move, approved by stockholders on May 14, 2024, aims to meet Nasdaq's $1.00 minimum bid price requirement but does not guarantee compliance. Post-split, Tharimmune will have approximately 785,978 shares outstanding, with proportional adjustments to equity-based awards and rights.
Tharimmune, Inc. (NASDAQ:THAR) will participate in two investor conferences in May. Randy Milby, CEO, will present at the Planet MicroCap Showcase: VEGAS 2024 and attend the EF Hutton Annual Global Conference. Investors can register online to meet with the company.
FAQ
What is the current stock price of Tharimmune (THAR)?
What is the market cap of Tharimmune (THAR)?
What is Tharimmune, Inc.'s primary focus?
What is TH104?
How did Tharimmune perform in its recent Phase 1 trial for TH104?
What are Tharimmune's plans for TH104 moving forward?
How much did Tharimmune raise in its recent public offering?
What partnerships does Tharimmune have?
What are the primary results from the Phase 1 trial of TH104?
What other projects are Tharimmune working on?
How is Tharimmune funded for its upcoming projects?
What can we expect from Tharimmune in the near future?
